Results of the ONTARGET and TRANSCEND studies: an update and discussion by Fitchett, David
© 2009 Fitchett, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2009:5 21–29 21
REVIEW
Results of the ONTARGET and TRANSCEND 
studies: an update and discussion
David Fitchett
St Michael’s Hospital, and University 
of Toronto, Ontario, Canada
Correspondence: David Fitchett
St Michael’s Hospital, 30, Bond St, Toronto, 
Ontario M5B 1W8, Canada
Tel +1 416 864 5627
Fax +1 416 8645159
Email ﬁ  tchettd@smh.toronto.on.ca
Abstract: The renin angiotensin aldosterone system (RAAS) plays an important role in the 
pathophysiology of cardiovascular disease. Angiotensin converting enzyme inhibitors (ACEi) 
have proven beneﬁ  t in reducing cardiovascular events in patients at high risk. Angiotensin 
receptor blockers (ARB) have been demonstrated to have beneﬁ  t in the management of heart 
failure and to be non-inferior to ACEi in patients with left ventricular dysfunction after a 
myocardial infarction (MI). Yet until now, there has been no trial to support the use of the ARB 
for vascular protection. The ONTARGET study showed that the ARB telmisartan conserved 
95% of the vascular protective properties of the ACEi ramipril, given at similar doses to a 
similar patient group as had been previously shownin the HOPE study to beneﬁ  t from ACE 
inhibition with ramipril. The TRANSCEND study in a similar population of patients who were 
intolerant of ACEi despite the primary endpoint being neutral, showed a trend to a beneﬁ  t 
for the combined secondary endpoint of cardiovascular death, MI and stroke, with excellent 
tolerance of the ARB. The reasons for neutral result of the TRANSCEND study result include an 
underpowered study, and pre-treatment with a RAAS inhibitor in a high proportion of patients. 
These studies indicate that an ARB can be used for vascular protection in high risk individuals 
in the place of an ACEi. However ACEi will probably remain the ﬁ  rst choice due to the greater 
body of supportive evidence.
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Introduction
Modulation of the renin angiotensin aldosterone system (RAAS) with angiotensin 
converting enzyme inhibitors (ACEi) reduces cardiovascular events in individuals at 
high risk.1 Clinical trials in hypertension and heart failure suggested the angiotensin 
receptor blockers (ARB) might have the vascular protective beneﬁ  ts of the ACEi with 
less adverse effects. However approximately 20% of patients, especially women and 
Asians, are unable to take an ACEi due to adverse effects such as cough, hypotensive 
symptoms, and angioneurotic edema. Consequently, an angiotensin receptor blocking 
agent (ARB) could be an alternative treatment to ACEi for vascular protection, with 
better patient tolerability.
The results of the ONTARGET2 and TRANSCEND3 studies, the largest 
clinical trial program ever conducted with an angiotensin receptor blocker, 
were recently reported. These trials examined strategies for cardiovascular risk 
reduction in high risk patients aged 55 years old, with coronary, cerebrovas-
cular disease, peripheral vascular disease or diabetes with target organ damage. 
ONTARGET compared the ARB telmisartan alone, or in combination with 
the ACEi ramipril, with ramipril treatment, for the protection against major 
cardiovascular events such as cardiovascular death, myocardial infarction (MI), 
stroke, or hospitalization for heart failure. TRANSCEND compared telmisartan Vascular Health and Risk Management 2009:5 22
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to placebo in patients who were intolerant of ACEi. 
The aims of the ONTARGET/TRANSCEND program were 
to learn whether adding the ARB telmisartan to proven 
therapy with an ACEi would further improve cardiovascular 
outcomes, and to establish the beneﬁ  ts of the ARB in this 
high risk population.
Vascular protection and RAAS 
modulation
Activation of the RAAS system is implicated in a range of 
cardiovascular and renal pathophysiology:4 the develop-
ment of atherosclerosis, the complications of atheroscle-
rosis such as acute MI, adverse myocardial remodeling 
and the development of heart failure, the development of 
systemic hypertension, and the development of progressive 
renal dysfunction. Angiotensin II mediated stimulation 
of the AT1 receptor increases arterial pressure, promotes 
oxidative stress, stimulates an inﬂ  ammatory response, 
and adversely alters the balance between the thrombotic 
and ﬁ  brinolytic state (Figure 1). Experimental evidence 
supports the hypothesis that both ACEi and the ARB classes 
of RAAS modulators have properties that may reduce the 
development of atherosclerosis and its complications. 
However differences between ACEi and ARB responses 
are observed, such that the ARBs might be pro-thrombotic 
by stimulating PAI-1 synthesis5 and and encourage plaque 
rupture by enhancing MMP-1 activity.6
Angiotensin converting enzyme 
inhibition and vascular protection
The SOLVD7 and SAVE8,9 studies were designed to test the 
hypothesis that RAAS modulation with an ACEi would slow 
the progression and development of heart failure. A surprising 
ﬁ  nding of both studies was a 20% reduction of the incidence 
of MI. These observations lead to the HOPE study,10 in which 
high dose ACEi with ramipril 10 mg daily reduced the risk 
of MI by 20%, stroke by 32%, and cardiovascular mortality 
by 26% in patients at high risk for cardiovascular events 
but without heart failure or a low left ventricular ejection 
fraction. The EUROPA study11 supported the observations 
of the HOPE study. Perindopril 8 mg daily in patients with 
coronary artery disease, reduced the endpoint of cardiovas-
cular mortality, non-fatal MI, and cardiac arrest by 20%. 
The PEACE study12 failed to show a beneﬁ  t from treatment 
with trandolapril 4 mg daily in patients with coronary artery 
disease. The study population was at low risk of cardiovas-
cular events and the trial underpowered to show a beneﬁ  t 
from the ACEi treatment. Coronary revascularization was the 
major contributor to the combined endpoint and occurred at 
similar rates in both treatment arms. In contemporary North 
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Figure 1 The role of the renin angiotensin aldosterone system in vascular disease. Angiotensin II (AII) is an important mediator of vascular damage that promotes the 
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American practice, aggressive coronary revascularization 
is probably a non-modiﬁ  able endpoint, as it is widely used 
independent of ischemia driven indications.
A combined analysis13 of the HOPE, EUROPA and 
PEACE studies showed that ACEi signiﬁ  cantly reduced 
all-cause mortality (7.8 vs 8.9% p = 0.0004), cardiovascular 
mortality (4.3 vs 5.2% p = 0.0002), non-fatal MI (5.3 vs 6.4% 
p = 0.0001), stroke (2.2 vs 2.8% p = 0.0004), coronary artery 
bypass surgery (6.0 vs 6.9%), but not percutaneous coronary 
intervention (7.4 vs 7.6% p = 0.48). Similar reductions of 
cardiovascular mortality and MI are observed in the ﬁ  ve 
trials in patients with heart failure or left ventricular systolic 
dysfunction.14
ARBs and vascular protection: 
pre-ONTARGET/TRANSCEND
Unlike the ACEi studies, most of which compared the 
ACEi with placebo, the ARBs have been compared with 
an active comparator. In heart failure trials, the comparator 
was usually an ACEi, whereas in hypertension trials the 
ARB was compared with other medication strategies. 
Placebo-controlled clinical trials with evaluation of clinical 
outcomes are either in ACEi-intolerant patients (CHARM 
alternative15,16) or in patients with diabetic nephropathy 
(RENAAL17 and IDNT18).
The CHARM study19 showed that the addition of the ARB 
candesartan to standard treatment, that included an ACEi 
reduced cardiovascular deaths and hospital admissions for 
heart failure. The combination of candesartan with an ACEi20 
was associated with a 17% reduction of both cardiovascular 
mortality and admission to hospital for heart failure com-
pared to those receiving only an ACEi. Patients receiving 
candesartan and an ACEi had a 23% (95% CI 2%–40%) 
reduction of non-fatal MI21 and a 12% (95% CI 13%–21%) 
reduction of cardiovascular death. Yet in the CHARM Alter-
native trial,15,16 where candesartan was compared to placebo 
in patients intolerant of ACEi, the incidence of MI increased 
by 52%, but cardiovascular death was 20% less (p = 0.02 
after covariate adjustment).
ARBs are effective and well tolerated antihypertensive 
agents. The LIFE study22 in older patients with moderately 
severe hypertension and left ventricular hypertrophy, showed 
the ARB losartan when compared to atenolol, resulted in a 
greater reduction of the combined end-point of cardiovas-
cular death, MI or stroke after equal blood pressure control. 
In patients with diabetes, losartan reduced cardiovascular and 
total mortality, but not MI. In the VALUE study,23 valsartan 
was not as effective an antihypertensive agent as amlodipine, 
yet there was no difference in the primary combined 
endpoint of cardiovascular mortality and morbidity. Yet, the 
valsartan-treated patients had a 19% relative increase in MI 
(p = 0.02) and a 15% (p = 0.08) increase in stroke compared 
to individuals receiving amlodipine.
ACEi in patients following MI reduce the risk of death 
by 26%, heart failure admissions by 27%, and recurrent 
MI by 20%.24 The ARB valsartan in the VALIANT study25 
was shown to be non-inferior to captopril for the reduc-
tion of all-cause mortality in patients with heart failure or 
left ventricular ejection fraction 40%. In this study MI 
occurred as frequently in valsartan as in captopril treated 
patients. Yet a discussion paper26 based on a meta-analysis 
of over 50, 000 patients, suggested that ARBs might increase 
the incidence of MI. An alternative explanation to this 
hypothesis is that the comparators in these trials (including 
ACEi and beta-adrenergic blockers) were more effective 
than an ARB for the reduction of coronary events.
The nephropathy studies RENAAL17 and IDNT18 showed 
that ARBs compared to placebo successfully slowed the 
progression of renal disease. Yet in these high risk patients, 
it is surprising that ARBs did not reduce vascular endpoints. 
It is likely these trials, primarily designed to examine renal 
endpoints, were underpowered to answer questions about 
cardiovascular events.
ONTARGET/TRANSCEND study 
design27
The Ongoing Telmisartan Alone and in Combination with 
Ramipril Global Endpoint Trial (ONTARGET)2 and Telmis-
artan Randomized Assessment Study in ACE Intolerant 
Subjects with Cardiovascular Disease (TRANSCEND)3 
studies examined the role of ARBs when used alone or in 
combination with an ACEi in high risk individuals with 
controlled hypertension (Figure 2). The design of the 
ONTARGET/TRANSCEND studies closely resembled that 
of the HOPE study, knowing that ramipril in this population 
was beneﬁ  cial and to allow comparisons of the outcomes of 
the two trials. The primary objective of ONTARGET was 
to determine whether the combination of telmisartan and 
ramipril was more effective than ramipril alone and to assess 
whether telmisartan alone was at least as effective as ramipril. 
TRANSCEND was a placebo-controlled study to determine 
whether telmisartan reduces vascular endpoints compared to 
placebo in patients intolerant of ACEi.
The primary endpoint for both ONTARGET and 
TRANSCEND was the combination of cardiovascular death, 
non-fatal MI, stroke, or hospitalization for heart failure. Vascular Health and Risk Management 2009:5 24
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Both studies included patients at high risk of coronary, 
peripheral or cerebrovascular events. Recruitment from 
730 centers in 40 countries for ONTARGET (n = 25,620) 
was completed in July 2003, and TRANSCEND (n = 6000) in 
May 2004. The planned follow-up period was 3.5 to 5.5 years. 
The study was designed to have a 93% power of showing 
a 13% superiority of telmisartan plus ramipril vs ramipril 
alone. In addition the study had an 89% power of showing 
the non inferiority of telmisartan compared to captopril whilst 
ensuring telmisartan has at least 50% of the ramipril effect 
at the upper 95th% conﬁ  dence limit. In TRANSCEND with 
3000 patients in each group, the study had a 94% power 
to show a 19% superiority of telmisartan over placebo, 
assuming an event rate of 5.1%/year, a recruitment period 
of 2 years and a maximum follow-up of 5.5 years.
Baseline characteristics in ONTARGET 
and TRANSCEND
The age of the patients in ONTARGET (66.4 years) and 
TRANSCEND (66.9 years) was slightly greater than in HOPE 
(65.9 years). Diabetes was present with a similar prevalence 
in ONTARGET (37.3%) and TRANSCEND (35.4%) as in 
HOPE (38.3%). ACEi (57.5%) and statin (61%) usage prior 
to enrollment was considerably greater than reported in HOPE 
(ACEi 11.6%, statins 28.9%). It is notable that there was 
a baseline 56% ACEi usage in TRANSCEND, in patients 
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no heart failure
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Figure 2 Study design and outcomes of ONTARGET and TRANSCEND studies.Vascular Health and Risk Management 2009:5 25
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supposedly intolerant to ACEi. The TRANSCEND population 
had several baseline differences from both ONTARGET and 
HOPE. In TRANSCEND there were a higher proportion of 
female patients (42.9%) than in ONTARGET (26.7%) or 
HOPE (26.7%).
Results of ONTARGET
Differences in blood pressure between the treatment groups 
during the trial were modest. The average difference of blood 
pressure for the telmisartan-treated groups (compared to 
ramipril) was 0.9/0.6 mmHg, and for telmisartan + ramipril 
2.4/1.4 mmHg.
After a median follow-up of 56 months the incidence 
of the primary outcome of cardiovascular death, non-fatal 
MI, stroke, or the development of heart failure did not dif-
fer signiﬁ  cantly between either the telmisartan + ramipril or 
the telmisartan groups compared to the ramipril group. The 
conﬁ  dence intervals of the relative risk of the telmisartan vs 
ramipril comparison were within the pre-speciﬁ  ed boundaries 
to show that telmisartan was not inferior to ramipril, and 
had conserved 95% of the efﬁ  cacy of ramipril (Figure 3). 
Consequently ONTARGET shows that telmisartan was as 
effective as ramipril, and well tolerated.
The combination of telmisartan and ramipril did not 
result in any improved outcome beyond that achieved by 
ramipril alone. Yet the combined treatment resulted in more 
hypotension, syncope, renal dysfunction, hyperkalemia, and 
a trend towards a greater risk of renal dysfunction requiring 
dialysis. A subsequent analysis28 of the renal outcomes of 
ONTARGET showed that the combination of telmisartan 
and ramipril increased the renal endpoints of dialysis and 
doubling of creatinine and death compared to treatment with 
the individual agents: ramipril 13.4%, telmisartan 13.5%, 
ramipril + telmisartan 14.5% RR 1.09 (p = 0.037) and dialysis 
and doubling of creatinine ramipril 2.03%, telmisartan 2.21%, 
ramipril + telmisartan 2.49% RR 1.24, (p = 0.038). Many of 
the dialysis events were for acute dialysis, probably resulting 
from acute renal failure due to excessive blood pressure 
reduction in patients with atherosclerotic renal artery disease. 
For the 700 patients with diabetic nephropathy, the combined 
telmisartan + ramipril treatment resulted in a non-signiﬁ  cant 
8% reduction of the combined endpoint of death, doubling 
of creatinine, or need for dialysis. Consequently, there is no 
beneﬁ  t of ACEi + ARB combination therapy in any group 
of patients included in the ONTARGET study, beyond a 
reduction of albuminuria.
TRANSCEND
The TRANSCEND study3 comparing telmisartan and 
placebo in high risk patients intolerant of ACEi failed to 
show a clear beneﬁ  t of ARB therapy. Blood pressure was 
reduced 4/2 mmHg by telmisartan. The primary end-point 
of death, MI, stroke or admission to hospital with heart 
failure occurred in 15.7% of patients receiving telmisartan 
and 17.0% receiving placebo (HR 0.92, p = 0.216). The 
secondary HOPE endpoint of death, MI, stroke (Figure 3) 
appeared to be reduced (13% vs 14.8%, HR 0.87, p = 0.048). 
However after adjustment for multiple comparisons, the 
difference was non-signiﬁ  cant (p = 0.068). Telmisartan was 
well tolerated in patients reported to be previously intolerant 
of ACEi, and fewer patients discontinued telmisartan than 
discontinued placebo treatment. Hypotensive symptoms 
were the commonest, yet very infrequent adverse event 
(telmisartan 0.98% vs placebo 0.54%) resulting in perma-
nent discontinuation of treatment. In addition the safety of 
telmisartan was good in the 377 patients who had previously 
had severe reactions to an ACEi.
The Prevention Regimen for Effectively Avoiding Second 
Strokes (PRoFESS) Study29 of more than 20,  000 patients, 
compared the effect of telmisartan 80 mg daily with placebo 
in the secondary prevention of cardiovascular events 
including a further stroke. Despite a blood pressure reduction 
of 3.8/2.0 mmHg there was no reduction of the incidence 
of subsequent stroke or major cardiovascular events. 
Relative Risk (95% Cl) P Value
<0.001
0.003
1.2 1.1 1.0 0.9 0.8
Telmisartan Better Ramipril Better
Main secondary outcome
Primary composite outcome
Figure 3 Relative risk for primary outcome (cardiovascular death, MI, stroke and hospitalization for heart failure) and secondary HOPE study outcome (cardiovascular death, 
MI or stroke). The conﬁ  dence interval is well within the predeﬁ  ned boundary for non-inferiority of telmisartan compared with ramipril.Vascular Health and Risk Management 2009:5 26
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Outcomes appeared to be improved for events that occurred 
after 6 months of treatment. In a pre-speciﬁ  ed combined 
analysis of TRANSCEND and PRoFESS with more than 
26,000 patients, benefit from telmisartan was seen after 
6 months treatment (cardiovascular death, MI, stroke, 
hospitalization for heart failure OR 0.86 (95% CI 0.80–0.94). 
However there was little or no beneﬁ  t in the ﬁ  rst 6 months after 
randomization (OR 1.12 95% CI 0.99–1.27). It is therefore 
possible that more prolonged treatment with telmisartan could 
have resulted in a greater beneﬁ  t. In TRANSCEND, the mean 
duration of treatment to the occurrence of a vascular event is 
only 2 ½ years: a short time frame by comparison of the time 
taken for blood pressure lowering or lipid-lowering agents to 
show signiﬁ  cant beneﬁ  t.
Discussion
ARB = ACEi?
The vascular protective property of ACEi has been shown 
in clinical trials and subsequent meta-analyses. Studies with 
ARBs in patients with hypertension, heart failure and renal 
disease have yielded conﬂ  icting results. The ONTARGET 
study in patients at high risk of cardiovascular events showed 
that telmisartan was non-inferior, as deﬁ  ned by pre-speciﬁ  ed 
boundaries, to the ACEi ramipril given at the same dose as 
had been proven to be beneﬁ  cial in the HOPE study. The study 
showed that telmisartan conserved 95% (95% CI 83.2–106.3) 
of the beneﬁ  ts of ramipril assessed by the primary composite 
outcome and 105% (95% CI 91.6–119.0) of the benefits 
assessed by the secondary outcome of cardiovascular death, 
MI and stroke. These beneﬁ  ts were observed in a high risk 
population with Death/MI/Stroke event rates similar to those 
observed in the index HOPE study (cardiovascular/year rates: 
ONTARGET 3.0%/year, HOPE 2.8%/year). Consequently 
the equivalence of telmisartan to the ACEi ramipril for 
clinical application has been conclusively demonstrated. The 
ONTARGET study has raised several questions about the 
generalizabilty of the ﬁ  ndings. Can we assume that all ARBs 
can be used to replace an ACEi? Does telmisartan have any 
special properties? Telmisartan has a long biological half-life, 
and has PPAR agonist properties in addition to those of an AT1 
receptor blocker. Whether PPAR agonist activity is beneﬁ  cial 
or harmful in this situation is unknown. Other ARBs in heart 
failure trials have shown equal vascular protection when 
added to treatment that included an ACEi (CHARM overall,20 
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Figure 4 TRANSCEND study comparing telmisartan 80 mg daily with placebo in high risk patients. Kaplan-Meier Curves for the secondary outcome of cardiovascular 
death, MI or stroke (HOPE study outcome). After statistical correction for multiple comparisons and overlap with the primary endpoint, the difference was not statistically 
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or compared to an ACEi (VALIANT25). Yet the same ARBs in 
other situations when compared to placebo have been associated 
with an increased risk for MI (CHARM alternative15,16 in ACE 
intolerant patients and VALUE23 in high vascular risk patients 
with hypertension. So there is some uncertainty whether other 
ARBs would have been non-inferior to ramipril if they had 
been tested in an ONTARGET-like trial. Furthermore we do 
not know the optimal dose of other agents. However, the dose 
of telmisartan for ONTARGET was chosen as that known to 
have an effective antihypertensive action: the same reasoning 
could be applied to select the dose of other ARBs for vascular 
protection.
Why no additional beneﬁ  t 
from ACEi + ARB?
The combination of ramipril and telmisartan resulted in no 
additional beneﬁ  t beyond that achieved with either drug 
alone. Furthermore the combination therapy was associated 
with an increased incidence of adverse effects including those 
related to symptomatic hypotension, a deterioration of renal 
function, and hyperkalemia. The ACEi/ARB combination did 
reduce blood pressure more than the single agent. As a part of 
the vascular protective beneﬁ  t of ACEi had previously been 
attributed to blood pressure reduction, it was surprising to see 
no additional beneﬁ  t with average BP 2.4/1.4 mmHg lower 
in the combined arm compared to ramipril treated patients. 
Perhaps maximal vascular protection had been achieved 
with ACEi or ARB alone, and a further reduction of BP and 
RAAS activity had no additional beneﬁ  t.
Is there an indication for combined 
ACEi + ARB?
The combination of ACEi and ARB has not been proven to be 
an effective antihypertensive strategy and is not recommended 
by the Canadian Hypertensive Education Program (CHEP) 
unless there are other compelling reasons for combination 
therapy such as with heart failure or renal disease. The 
ONTARGET study shows that in the population studied 
there is no reason to combine ACEi and ARB. For patients 
with severe heart failure the CHARM Overall20 study with 
candesartan appears to support combined therapy. However 
the choice and dose of ACEi was not speciﬁ  ed and similar risk 
reductions were seen whether or not the patient was taking 
an ACEi. When the ACEi and dose were determined by the 
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Figure 5 Relative risks for secondary HOPE study endpoint of cardiovascular death, MI and stroke in the TRANSCEND study.Vascular Health and Risk Management 2009:5 28
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trial design as in VALIANT25 and ONTARGET, there was 
no additional beneﬁ  t from the combination of ACEi and ARB 
beyond that of the single agent.
Combined ACEi and ARB treatment appears to reduce 
proteinuria more than the individual agents. Whether this 
is a blood pressure lowering effect is uncertain. The only 
evidence to show that combined ACEi and ARB treatment 
slows the progression of renal disease comes from the 
COOPERATE study;30 the results of which have recently 
been discredited and considered to be unreliable.31
Was telmisartan better than placebo?
The results of the TRANSCEND study showed that there was 
no signiﬁ  cant difference in either the primary or secondary 
outcomes in patients receiving either telmisartan or placebo. 
The secondary HOPE endpoint of death/MI/stroke appeared to 
be reduced by telmisartan, yet the difference did not remain sta-
tistically signiﬁ  cant after adjustments for multiple comparisons. 
Does this mean telmisartan is no better than placebo, despite 
being shown to retain almost all the vascular protective proper-
ties of ramipril in the ONTARGET study? There are several 
possible reasons for this apparent discrepancy. Firstly that the 
TRANSCEND study was underpowered, with too low event 
rates and an inadequate follow-up period to show an ambitious 
19% relative risk reduction. For the secondary HOPE endpoint 
the event rate in the placebo group of the TRANSCEND study 
was 3.2%/ year but in the HOPE study the event rate was 4.4%/ 
year. Yet in the EUROPA study, perindopril did show a 20% 
reduction of the combined endpoint of cardiovascular death/MI 
and cardiac arrest with lower event rates than were observed in 
the HOPE study and over a 4.2-year observation period.
A second possible explanation is the legacy effect of 
pre-treatment with either ACEi or ARB. The design and 
baseline characteristics paper27 indicates that 58.1% of 
patients were receiving an ACEi and 29.9% an ARB at the 
time of randomization. In the HOPE-TOO study,32 there were 
persistent beneﬁ  ts from the 5-year period of ramipril treatment, 
that remained for at least 3 (median 2.6 years) after the random-
ization period ended. A similar persistent legacy of treatment 
was observed in the AIREX study of post-myocardial heart 
failure.33 Hence it is possible that the beneﬁ  ts of telmisartan 
were reduced because of the persistent legacy of pre-treatment 
with either ACEi or ARB in the placebo group.
Application of ONTARGET 
and TRANSCEND
The results of these two important trials indicate that for 
patients at high risk for vascular events, either ramipril or 
telmisartan can be used to reduce event rates. Whether a 
physician uses an ACEi or ARB for vascular protection 
will depend upon many factors, including habit, cost and 
adverse effects of treatment. Yet telmisartan was shown to be 
safe in ACEi intolerant patients and from the ONTARGET 
study preserved almost all the vasculoprotective beneﬁ  ts 
of ramipril. Telmisartan was well tolerated with less 
patients discontinuing treatment due to cough (telmisartan 
93 vs ramipril 360) or angio-edema (10 vs 25). Although 
hypotension was more frequent with telmisartan (229 vs 
149), the incidence of syncope was very similar (19 vs 15). 
Therefore it would not be unreasonable, despite the results of 
TRANSCEND, to recommend ARB usage in ACEi intolerant 
individuals. Guidelines have started to recommend ACEi and 
ARBs as alternative choices for vascular protection especially 
in high risk individuals with diabetes.34
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